BGXX Stock Overview
Produces and exports legal cannabis, cannabis extracts, and tetrahydrocannabinol in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Bright Green Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.038 |
| 52 Week High | US$0.54 |
| 52 Week Low | US$0.034 |
| Beta | 0.67 |
| 11 Month Change | -82.64% |
| 3 Month Change | -84.80% |
| 1 Year Change | -90.28% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.85% |
Recent News & Updates
Shareholder Returns
| BGXX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.9% | -2.7% | 0.9% |
| 1Y | -90.3% | 21.5% | 32.4% |
Return vs Industry: BGXX underperformed the US Pharmaceuticals industry which returned 22.2% over the past year.
Return vs Market: BGXX underperformed the US Market which returned 32.1% over the past year.
Price Volatility
| BGXX volatility | |
|---|---|
| BGXX Average Weekly Movement | 28.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BGXX's share price has been volatile over the past 3 months.
Volatility Over Time: BGXX's weekly volatility has increased from 22% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 5 | Groovy Singh | www.brightgreen.us |
Bright Green Corporation produces and exports legal cannabis, cannabis extracts, and tetrahydrocannabinol in the United States. Its products are used in research, manufacturing, and export, as well as for production of medical cannabis products and preparations. The company was incorporated in 2019 and is based in Grants, New Mexico.
Bright Green Corporation Fundamentals Summary
| BGXX fundamental statistics | |
|---|---|
| Market cap | US$10.30m |
| Earnings (TTM) | -US$9.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs BGXX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGXX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.92m |
| Earnings | -US$9.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.052 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 5.2% |
How did BGXX perform over the long term?
See historical performance and comparison